Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Chugai Pharmaceutical Co Ltd    4519   JP3519400000

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2017 526 B
EBIT 2017 -
Net income 2017 72 605 M
Finance 2017 178 B
Yield 2017 1,02%
Sales 2018 555 B
EBIT 2018 -
Net income 2018 80 302 M
Finance 2018 192 B
Yield 2018 1,16%
P/E ratio 2017 45,13
P/E ratio 2018 39,92
EV / Sales2017 6,03x
EV / Sales2018 5,69x
Capitalization 3 347 B
More Financials
Company
Chugai Pharmaceutical Co., Ltd. engages in the manufacture, sale, import, and export of pharmaceutical.Its products include oncology drugs, bone and joint drugs, renal diseases drugs, and therapeutic antibodies.The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo,... 
More about the company
Surperformance© ratings of Chugai Pharmaceutical Co L
Trading Rating : Investor Rating :
More Ratings
Latest news on CHUGAI PHARMACEUTICAL CO L
10:23a CHUGAI PHARMACEUTICAL : “Atezolizumab” plus “Avastin” Si..
12/07 CHUGAI PHARMACEUTICAL : Emicizumab Every Four Weeks Showed Positive Interim Resu..
12/04 CHUGAI PHARMACEUTICAL : Organizational and Personnel Changes
11/30 CHUGAI PHARMACEUTICAL : TWOCELLS and Chugai Announce Performing Surgery of the F..
11/25 CHUGAI PHARMACEUTICAL : Chugais HEMLIBRA Receives the Worlds First Regulatory Ap..
11/23 CHUGAI PHARMACEUTICAL : Immune Checkpoint Inhibitor 'Atezolizumab' Significantly..
11/22 CHUGAI PHARMACEUTICAL : Bispecific Antibody Emicizumab Meets Primary Endpoint in..
11/21 CHUGAI PHARMACEUTICAL : HEMLIBRA® Receives the World's First Regulatory Approval..
11/21 CHUGAI PHARMACEUTICAL : HEMLIBRA Receives the World's First Regulatory Approval ..
11/20 CHUGAI PHARMACEUTICAL : Bispecific Antibody Emicizumab Meets Primary Endpoint in..
More news
Sector news : Pharmaceuticals - NEC
09:59a European shares edge up near four-week highs, helped by banks
07:45aDJROCHE : Reports Positive Results From IMmotion151 Kidney Cancer Trial
07:32a ROCHE : Tecentriq cocktail slows kidney cancer progression
07:08a Monsanto offers cash to U.S. farmers who use controversial chemical
07:03a Merck raises stakes in lung cancer as rivals close in
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/25 Chugai Pharmaceutical Co., Ltd. ADR 2017 Q3 - Results - Earnings Call Slides
10/25 ROCHE : Buying The Dip
10/25 Chugai Pharmaceutical reports Q3 results
07/27 Chugai Pharmaceutical reports 1H results
07/12 Chugai Pharmaceutical (CHGCY) Presents R&D Conference Call - Slideshow
Chart CHUGAI PHARMACEUTICAL CO L
Duration : Period :
Chugai Pharmaceutical Co L Technical Analysis Chart | 4519 | JP3519400000 | 4-Traders
Technical analysis trends CHUGAI PHARMACEUTICAL CO L
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 5 452  JPY
Spread / Average Target -8,8%
EPS Revisions
Managers
NameTitle
Osamu Nagayama Chairman & Chief Executive Officer
Tatsuro Kosaka President, COO & Representative Director
Yoshio Itaya Chief Financial Officer & Director
Keiji Kono Executive Officer & Manager-IT Supervisory Section
Motoo Ueno Vice Chairman & Head-Audit
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO LTD78.24%29 496
JOHNSON & JOHNSON21.23%377 698
NOVARTIS11.34%218 728
PFIZER9.48%213 036
ROCHE HOLDING LTD.6.19%208 877
MERCK AND COMPANY-7.68%151 559